Japan Multiomics Market Size & Outlook, 2026-2033
Global Market
Related Markets
Japan multiomics market highlights
- The Japan multiomics market generated a revenue of USD 112.5 million in 2025 and is expected to reach USD 391.8 million by 2033.
- The Japan market is expected to grow at a CAGR of 16.9% from 2026 to 2033.
- In terms of segment, bulk multiomics was the largest revenue generating type in 2025.
- Single-cell Multiomics is the most lucrative type segment registering the fastest growth during the forecast period.
Multiomics market data book summary
| Market revenue in 2025 | USD 112.5 million |
| Market revenue in 2033 | USD 391.8 million |
| Growth rate | 16.9% (CAGR from 2026 to 2033) |
| Largest segment | Bulk multiomics |
| Fastest growing segment | Single-cell Multiomics |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single-cell Multiomics, Bulk Multiomics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Danaher Corp, Shimadzu Corp, Bruker Corp, Qiagen NV, Agilent Technologies Inc, BD, Revvity Inc, BGI Group |
Other key industry trends
- In terms of revenue, Japan accounted for 3.6% of the global multiomics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China multiomics market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 346.3 million by 2033.
Healthcare and clinical research service providers in Japan have been progressively incorporating sequencing technologies over the past few years and are projected to play a significant role in the Asia Pacific genomics revenue share.
For instance, in April 2022, the Okinawa Institute of Science and Technology Graduate University (OIST), in collaboration with Tokyo-based Corundum Systems Biology Inc., introduced a research project aimed at developing a complete automated system for disease prediction by fiscal year 2024.
Furthermore, numerous hospitals in Japan have initiated the use of Next-Generation Sequencing (NGS)- based mutational profile screening for patients diagnosed with solid tumors, aiding in guiding patients toward appropriate clinical trials. The Ministry of Health, Labour and Welfare of Japan has also approved various cancer gene panels to be employed in clinical practice.
No credit card required*
Publish Date: Jun 12, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Multiomics Market Scope
Multiomics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Shimadzu Corp | View profile | 15,284 | 1, Nishinokyo-Kuwabara-cho, Nakagyo-ku, Kyoto, Japan, 604-8511 | www.shimadzu.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Revvity Inc | View profile | 11,500 | 940 Winter Street, Waltham, MA, United States, 02451 | www.revvity.com |
| Bruker Corp | View profile | 9,707 | 40 Manning Road, Billerica, MA, United States, 01821 | www.bruker.com |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | www.bd.com |
| BGI Group | View profile | 5001-10000 | Shenzhen, Guangdong, China, Asia | www.genomics.cn/ |
Japan Multiomics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Multiomics Market Outlook will help companies and investors design strategic landscapes.
Bulk Multiomics was the largest segment with a revenue share of 77.78% in 2025.
Horizon Databook has segmented the Japan multiomics market based on single-cell multiomics, bulk multiomics covering the revenue growth of each sub-segment from 2021 to 2033.
Healthcare and clinical research service providers in Japan have been progressively incorporating sequencing technologies over the past few years and are projected to play a significant role in the Asia Pacific genomics revenue share.
For instance, in April 2022, the Okinawa Institute of Science and Technology Graduate University (OIST), in collaboration with Tokyo-based Corundum Systems Biology Inc., introduced a research project aimed at developing a complete automated system for disease prediction by fiscal year 2024.
Furthermore, numerous hospitals in Japan have initiated the use of Next-Generation Sequencing (NGS)- based mutational profile screening for patients diagnosed with solid tumors, aiding in guiding patients toward appropriate clinical trials. The Ministry of Health, Labour and Welfare of Japan has also approved various cancer gene panels to be employed in clinical practice.
- Japan Multiomics Market Type Outlook (Revenue, USD Million , 2021-2033)
- Single-cell Multiomics
- Bulk Multiomics
- Japan Multiomics Market Platform Outlook (Revenue, USD Million , 2021-2033)
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
- Japan Multiomics Market Product & Service Outlook (Revenue, USD Million , 2021-2033)
- Services
- Product
- Japan Multiomics Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical & Biotechnology Companies
- Others
- Academic & Research Institutes
- Japan Multiomics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Immunology
- Cell Biology
- Oncology
- Neurology
Reasons to subscribe to Multiomics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Multiomics Market Outlook databook
- Our clientele includes a mix of Multiomics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Multiomics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Multiomics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Multiomics Market, 2021-2033 (US$M)
Japan Type - Multiomics Market Statistics, 2025 - 2033 (US$M)
